(Reuters) -Apple will host its annual fall event on September 9, according to an invite on Tuesday, where the company is expected to unveil new
Category: Newsletters
Nvidia results to spotlight fallout of China-US trade war
By Arsheeya Bajwa (Reuters) -Nvidia’s business in China will be the focus of investors when the AI chipmaker reports earnings on Wednesday, following an unusual
Buffett shoots down talk of Berkshire railroad merger, CSX shares slide
“I Made Millions in the Tech Boom. Here’s Where I’d Put My Money Today” Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple
Spotify flags price rises as it introduces new services, FT reports
(Reuters) -Spotify will raise prices as it invests in new features and targets 1 billion users, the Financial Times reported on Sunday citing the music
Trump crime crackdown deploys troops in Washington’s safest sites
“I Made Millions in the Tech Boom. Here’s Where I’d Put My Money Today” “Fed Proof” Your Bank Account with THESE 4 Simple Steps [sponsor] Trump
Elliott, Gold Reserve affiliates work on offers for Citgo parent as bidding end looms
By Marianna Parraga HOUSTON (Reuters) -A U.S. court officer is preparing to recommend a winner in an auction for shares of Citgo Petroleum’s parent company,
U.S. sectors in spotlight ahead of Fed’s Jackson Hole gathering
By Shashwat Chauhan and Johann M Cherian (Reuters) -Wall Street will search for confirmation of a September interest rate cut when Federal Reserve Chair Jerome
Walmart results show consumer resilience; shares down after recent rally
What if the money sitting in your account right now… … is already enough for you to never worry about paying bills again? I’m
Walmart results show consumer resilience; shares down after recent rally
What if the money sitting in your account right now… … is already enough for you to never worry about paying bills again? I’m
Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists
By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug to its